Huadong Medicine 2 major BD deals in 7 days!

On February 28, Huadong Medicine announced that it signed an equity investment agreement and an exclusive product license agreement with Heidelberg Pharma AG, a German listed company

At the same time, Huadong Medicine will obtain the exclusive license of Heidelberg Pharma's two research products HDP-101 and HDP-103in 20 Asian countries and regions including Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region, South Korea and Singapore.

Huadong Pharma will pay Heidelberg Pharma an upfront payment of $20 million, development, registration and sales milestone payments of up to $449 million , as well as tiered royalties on net sales

Huadong Medicine said that this time, in cooperation with Heidelberg Pharma, a variety of ADC innovative products have been introduced, which further enriched the company's innovative product pipeline in the field of oncology, and achieved a differentiated in-depth layout in the ADC field

In recent years, Huadong Medicine has successively invested, held and incubated a number of domestic biotechs, including investing in the antibody R&D and production company Quanxin Bio , and Nuo Ling Bio ,which has ADC linker and conjugation technology.

Introducing an exclusive new ADC technology platform

According to the announcement, Heidelberg Pharma is one of the top Biotechs in ADC drug research and development in the world.

It can be seen that the dieviniHopp Fund focuses on investing in biotech companies with cutting-edge technologies in the segmented track, including HeidelbergPharma, which Huadong Medicine intends to acquire this time, and is also a star company in global ADC drug development

HeidelbergPharma owns the exclusive ATAC® platform (AntibodyTargeted Amanitin Conjugate, antibody-Amanita conjugate) , is the first company in the world to successfully develop Amanitin (Amanita) and its derivatives for cancer treatment, and successfully utilize The unique biological properties of the toxin open up an entirely new approach to treatment
.

It is worth mentioning that Amanitin is the only RNA polymerase II inhibitor known in the world, which has the potential to break through drug resistance or destroy tumor cells in the silent phase, and can effectively prevent tumor metastasis and recurrence
.
Compared with traditional ADC drugs, Amanitin has strong hydrophilicity and can effectively reduce ATAC® aggregation, is not easy to accumulate in other tissues, significantly reduces the cytotoxicity of free toxins, and reduces liver toxicity
.
In addition, the biomarker Del (17p) can be used for precision treatment to improve the probability of successful clinical trials
.

Based on the ATAC® platform, Heidelberg Pharma has established a differentiated and advanced R&D pipeline .
At the same time, it has also successfully carried out a number of external cooperation to promote the transformation of technological achievements
.

This time, Huadong Medicine introduced two ADC innovative products HDP-101 and HDP-103 from Heidelberg Pharma
.
HDP-101 targets BCMA and is currently conducting an overseas Phase I/IIa clinical trial for the treatment of relapsed/refractory multiple myeloma, and has completed the first subject dosing on February 15, 2022
.
HDP-103 targets PSMA (prostate-specific membrane antigen) and is currently conducting preclinical studies with the target indication for metastatic castration-resistant prostate cancer (mCRPC)
.
PSMA is overexpressed in nearly all prostate cancer patients but restricted in normal tissues, making it an ideal target for the development of ATAC® drugs
.

In addition, according to the cooperation agreement, Huadong Medicine will also obtain the exclusive right to choose two other Heidelberg Pharma products under development, HDP-102 and HDP-104, and the right to negotiate first for another two follow-up products under development
.
In the future, Heidelberg Pharma is expected to deliver a rich ADC product pipeline to Huadong Medicine
.

Build a world-class  independent R&D industrial platform in the ADC field

In recent years, ADC drug research and development, investment and financing have continued to be hot , and overseas big pharmas such as Johnson & Johnson and Eli Lilly have entered the market one after another, and a number of ADC drug biotechs have emerged in China
.
According to an article published by Nature Reviews, the market size of the first 10 ADC drugs on the market is expected to exceed US$16.
4 billion by 2026.
CITIC Securities analysis pointed out that assuming that the first 10 ADC drugs occupy 40% of the market share, it is predicted that global sales will be 40%.
$41 billion
.

The current competitive landscape of ADC drugs is good, and there is no common phenomenon of target clustering.
Coupled with the continuous iteration of technology, it is expected to avoid involution and explore a path of differentiated innovation
.

Huadong Medicine has made important staged progress in the field of ADC.
Mirvetuximab, developed in cooperation with ImmunoGen in the United States, is the world's first ADC candidate for folate receptor alpha (FRα) positive ovarian cancer.
It is expected to have high FRα expression and platinum resistance.
of ovarian cancer patients with new precision treatment options
.
As of the end of 2021, the SORAYA study, the pivotal single-arm clinical trial of Mirvetuximab in the United States, has reached the primary endpoint of the study, the Phase I clinical trial in China has completed the first subject dosing, and another international multicenter randomized controlled Phase III clinical trial has been completed.
China's first research center for MIRASOL research has been launched
.
ImmunoGen expects to file a BLA application for IMGN853 in the US in the first quarter of 2022
.

As the world's largest drug market for oncology drugs, there are still many clinical needs that cannot be met, and the market growth potential is huge
.
For example, IQVIA data shows that the global multiple myeloma drug market has grown from $7.
774 billion in 2016 to $16.
201 billion in 2020, with a CAGR of about 20%
.
Therefore, this overseas investment cooperation will also help to accelerate Huadong Medicine's international innovation layout in the field of anti-tumor
.

At present, through the driving model of independent research and development and external cooperation, Huadong Medicine has formed a rich product pipeline in the field of oncology, and has nearly ten global innovative drugs, covering the fields of solid tumors and hematological tumors
.

From: official information of Huadong Medicine

2 blockbuster BD deals in 7 days

A week ago, Huadong Medicine just announced the introduction of two innovative autoimmune products from Kiniksa with a down payment of US$22 million + milestone payment of not more than US$640 million .
Through the driving model of independent research and development and external cooperation, it has formed a rich and differentiated immune field.
With a streamlined pipeline layout, product indications cover dermatology, rheumatology, cardiovascular, respiratory, nephrology, transplant surgery and other departments.
It is one of the pharmaceutical companies with the most comprehensive coverage in the field of immunization in China
.

Although the impact of the new crown epidemic has continued since 2020, Huadong Medicine has always adhered to the international innovation strategy
.
In the past three years, while consolidating its own basic advantages, Huadong Medicine has differentiated its layout in the ADC field, drawn a forward-looking blueprint for industrial microorganisms, and strategically grabbed the blue ocean of high-end medical beauty.
, showing a professional, international and youthful corporate >
.

Big waves are chasing the sand, and the domestic biopharmaceutical industry innovation wave is surging and surging.
Only by daring to face the difficulties and catching up, can we move forward on the waves
.